Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain

Show other versions (1)

<h4>Aims</h4> A Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients with non-valvular atrial fibri...

Full description

Bibliographic Details
Main Authors: Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi, Jean-Baptiste Briere
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020681/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020681/?tool=EBI

Similar Items